 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
52 News |  |
| 12» |
- || ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - May 28, 2024
P2, N=212, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Jun 2024 --> May 2025 | Trial primary completion date: Jun 2024 --> May 2025
- || miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment closed: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - May 13, 2024
P1, N=119, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Jun 2024 --> May 2025 | Trial primary completion date: Jun 2024 --> May 2025 Recruiting --> Active, not recruiting
- | miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Phase classification: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - Mar 12, 2024
P1, N=140, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Phase classification: P1a/1b --> P1
- brigimadlin (BI 907828) / Boehringer Ingelheim
Efficacy and safety of brigimadlin (BI 907828), an MDM2 (Poster Bd # C12) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_431;
P1, P1a/1b
A Phase IIa/IIb trial of brigimadlin in patients with MDM2-amplified, TP53 wild-type BTC and other solid tumors is ongoing (Brightline-2). Clinical trial information: NCT03449381 and NCT03964233.
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Jul 31, 2023
P1, N=146, Completed, Sponsor: Boehringer Ingelheim
Clinical trial information: NCT03449381 and NCT03964233. Active, not recruiting --> Completed
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Jun 22, 2023
P1, N=172, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- BI 907828 / Boehringer Ingelheim
Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials. (Available On Demand; Poster Board No. C13) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_433;
P1a/1b, P2
A phase IIa/IIb trial of BI 907828 (45 mg q3w) in patients with BTC is planned to start recruitment at the end of 2022 (NCT05512377). Clinical trial information: NCT03449381 and NCT03964233.
- || ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Nov 29, 2022
P2, N=212, Active, not recruiting, Sponsor: Boehringer Ingelheim
Clinical trial information: NCT03449381 and NCT03964233. Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial primary completion date, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Nov 16, 2022
P1, N=146, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024 Trial primary completion date: Nov 2022 --> Aug 2023
- BI 907828 / Boehringer Ingelheim
PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2âTUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS () - Sep 9, 2022 - Abstract #CTOS2022CTOS_413;
P1a/1b
The doublet combination of BI 907828 plus ezabenlimab showed a manageable safety profile and early signs of anti-tumor activity. Eleven patients remain on treatment; recruitment is ongoing.
- | miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Aug 25, 2022
P1, N=146, Active, not recruiting, Sponsor: Boehringer Ingelheim
Eleven patients remain on treatment; recruitment is ongoing. Trial completion date: Nov 2022 --> Aug 2023
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Aug 25, 2022
P1, N=172, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Nov 2022 --> Aug 2023 Trial completion date: Aug 2022 --> Jun 2023 | Trial primary completion date: Aug 2022 --> Jun 2023
- | miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Journal: Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. (Pubmed Central) - Jun 28, 2022
P1
Overall, ezabenlimab and BI 754111 bound to their respective targets with high affinity and prevented ligand binding. Combining ezabenlimab with BI 754111 enhanced in vitro activity versus monotherapy, supporting clinical investigation of this combination (NCT03156114; NCT03433898).
- miptenalimab (BI 754111) / Boehringer Ingelheim, BI 907828 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors. (Available On Demand; 87) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5132;
P1a/1b
The doublet combination of BI 907828 plus ezabenlimab showed a manageable safety profile and early signs of anti-tumor activity. Eleven pts remain on treatment; recruitment is ongoing.
- || miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - Mar 10, 2022
P1a/1b, N=144, Recruiting, Sponsor: Boehringer Ingelheim
Eleven pts remain on treatment; recruitment is ongoing. Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Oct 2023 --> Sep 2024
- ||| ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Feb 22, 2022
P2, N=212, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Oct 2023 --> Sep 2024 Recruiting --> Active, not recruiting
- || miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - Dec 1, 2021
P1a/1b, N=144, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial completion date: May 2024 --> Jun 2025 | Trial primary completion date: Sep 2022 --> Oct 2023
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial primary completion date, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Nov 4, 2021
P1, N=146, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: May 2024 --> Jun 2025 | Trial primary completion date: Sep 2022 --> Oct 2023 Trial primary completion date: May 2021 --> Nov 2022
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Oct 20, 2021
P1, N=172, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: May 2021 --> Nov 2022 Trial completion date: Dec 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Aug 2022
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Oct 5, 2021
P1, N=146, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Dec 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Aug 2022 Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Oct 2021 --> May 2021
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial termination, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Sep 17, 2021
P1, N=8, Terminated, Sponsor: Boehringer Ingelheim
Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Oct 2021 --> May 2021 Completed --> Terminated; Due to company decision.
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Aug 27, 2021
P1, N=172, Active, not recruiting, Sponsor: Boehringer Ingelheim
Completed --> Terminated; Due to company decision. Trial completion date: Aug 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Dec 2022
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Apr 22, 2021
P1, N=146, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Aug 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Dec 2022 Trial completion date: May 2021 --> Nov 2021 | Trial primary completion date: Apr 2021 --> Oct 2021
- miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
[VIRTUAL] Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer (Track 7) - Mar 2, 2021 - Abstract #JSMO2021JSMO_672;
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Dec 19, 2020
P1, N=8, Completed, Sponsor: Boehringer Ingelheim
Trial completion date: May 2021 --> Nov 2021 | Trial primary completion date: Apr 2021 --> Oct 2021 Active, not recruiting --> Completed | Trial completion date: Mar 2021 --> Dec 2020 | Trial primary completion date: Dec 2020 --> Feb 2020
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Dec 17, 2020
P1, N=145, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Trial completion date: Mar 2021 --> Dec 2020 | Trial primary completion date: Dec 2020 --> Feb 2020 Active, not recruiting --> Recruiting
- BI 754111 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
[VIRTUAL] Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_171;
P1
Treatment was well tolerated and preliminary antitumor activity was seen. Addition of LAG3 did not improve ORR beyond that expected for an anti-PD-1 monotherapy in gastric and esophageal cancer without patient selection.
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Nov 18, 2020
P1, N=146, Active, not recruiting, Sponsor: Boehringer Ingelheim
Addition of LAG3 did not improve ORR beyond that expected for an anti-PD-1 monotherapy in gastric and esophageal cancer without patient selection. Recruiting --> Active, not recruiting
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Oct 13, 2020
P1, N=173, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Oct 7, 2020
P1, N=8, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Oct 5, 2020
P2, N=260, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Suspended --> Recruiting
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Sep 9, 2020
P1, N=215, Recruiting, Sponsor: Boehringer Ingelheim
Suspended --> Recruiting Trial completion date: Nov 2021 --> Aug 2021 | Trial primary completion date: Nov 2021 --> Aug 2021
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment change, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Sep 9, 2020
P1, N=8, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Nov 2021 --> Aug 2021 | Trial primary completion date: Nov 2021 --> Aug 2021 N=15 --> 8
- || miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - Aug 7, 2020
P1a/1b, N=170, Recruiting, Sponsor: Boehringer Ingelheim
N=15 --> 8 Trial completion date: Aug 2023 --> May 2024 | Trial primary completion date: Dec 2021 --> Sep 2022
- ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Jul 2, 2020
P2, N=260, Suspended, Sponsor: Boehringer Ingelheim
Trial completion date: Aug 2023 --> May 2024 | Trial primary completion date: Dec 2021 --> Sep 2022 Trial completion date: Feb 2023 --> May 2023 | Trial primary completion date: Feb 2023 --> May 2023
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment change, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Jul 1, 2020
P1, N=15, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Feb 2023 --> May 2023 | Trial primary completion date: Feb 2023 --> May 2023 N=40 --> 15
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Jun 11, 2020
P1, N=40, Recruiting, Sponsor: Boehringer Ingelheim
N=40 --> 15 Suspended --> Recruiting
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Jun 4, 2020
P1, N=156, Recruiting, Sponsor: Boehringer Ingelheim
Suspended --> Recruiting Suspended --> Recruiting
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - May 21, 2020
P1, N=215, Recruiting, Sponsor: Boehringer Ingelheim
Suspended --> Recruiting Suspended --> Recruiting
- ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - May 21, 2020
P2, N=260, Suspended, Sponsor: Boehringer Ingelheim
Suspended --> Recruiting Trial completion date: Dec 2021 --> Feb 2023 | Trial primary completion date: Dec 2021 --> Feb 2023
- BI 754111 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: Biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_131;
P1
BI 754111 plus BI 754091 showed encouraging results in this IO-refractory MSS mCRC population. Biomarker analyses showed activation of the immune system in peripheral blood and the tumor, consistent with other CPIs.
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - May 14, 2020
P1a/1b, N=170, Recruiting, Sponsor: Boehringer Ingelheim
Biomarker analyses showed activation of the immune system in peripheral blood and the tumor, consistent with other CPIs. Suspended --> Recruiting
- BI 754111 / Boehringer Ingelheim, BI 907828 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
[VIRTUAL] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors. (Poster Board 390) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1607;
P1a/1b
Phase Ib will include at least 140 evaluable pts (80 pts in cohort 1 and 20 pts each in cohorts 2–4). Research Funding: Boehringer Ingelheim
- BI 754111 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
[VIRTUAL] Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors. (Poster Board 127) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1339;
P1, P2
The combination of BI 754111 and BI 754091 had a manageable safety profile, similar to other checkpoint inhibitors. Research Funding: Boehringer Ingelheim
- BI 754111 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
[VIRTUAL] An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors. (Poster Board 118) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1331;
P1
The recommended dose for the combination was determined as BI 754091 240 mg plus BI 754111 600 mg q3w. Treatment was well tolerated and consistent with that observed in the global trial.
- |||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial suspension, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Apr 7, 2020
P1, N=215, Suspended, Sponsor: Boehringer Ingelheim
Treatment was well tolerated and consistent with that observed in the global trial. Recruiting --> Suspended
- |||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial suspension, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Apr 6, 2020
P1, N=156, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended Recruiting --> Suspended
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial suspension, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Apr 6, 2020
P1, N=40, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended Recruiting --> Suspended
- |||||| ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial suspension, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Apr 6, 2020
P2, N=260, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended Recruiting --> Suspended
- |||| miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial suspension: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - Apr 5, 2020
P1a/1b, N=170, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended Recruiting --> Suspended